Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women

Oncology

Volumn 57, Issue 4, 1999, Pages 330-340

  Vadgama, Jaydutt V ^a   Wu, Yanyuan ^a   Datta, Geetanjali ^a   Khan, Huma ^a   Chillar, Ram ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

African American women; Breast cancer; Hispanic women; IGF I; IGFBP3; Oncology

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NEGRO; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 0032702836     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012052     Document Type: Article

References (53)

1. Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10:68-91.
2. Werner H, Adamo M, Roberts CT Jr, LeRoith D: Molecular and cellular aspects of insulin-like growth factor action. Vitam Horm 1994; 48:1-58.
3. Shimatsu A, Rotwein P: Mosaic evolution of the insulin-like growth factors. Organization, sequence and expression of the rat insulin-like growth factor I gene. J Biol Chem 1987;262: 7894-7900.
4. Clemmons D: IGF binding proteins: Regulation of cellular actions. Growth Regul 1992;2: 80-87.
5. Werner H, Woloschack M, Stannard B, ShenOrr Z, Roberts CT Jr, LeRoith D: The insulin-like growth factor I receptor: Molecular biology, heterogeneity, and regulation; in LeRoith D (ed): Insulin-Like Growth Factors: Molecular and Cellular Aspects. Boca Raton, CRC Press, 1991, pp 17-47.
6. Werner H, LeRoith D: The role of the insulin-like growth factor system in human cancer; in Vande Woude GF, Klein G (eds): Advances in Cancer Research. New York, Academic Press, 1996, vol 68, pp 184-223.
7. Pratt SE, Pollack MN: Estrogen and antiestrogen modulation of human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193-5198.
8. Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Insulin-like growth factor binding protein I expression inhibits insulin-like growth factor-I action in MCF-7 breast cancer cells. Cell Growth Differ 1994;5:73-77.
9. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49: 415-421.
10. Hankinson SE, Willett WC, Colditz GA, Hunter DJ: Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393-1396.
11. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
12. Barinaga M: Study suggests new way to gauge prostate cancer risk. Science 1998;279:475.
13. Holly J: Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet 1998;351:1373-1374.
14. Editorial: IGF binding protein-3 protease regulation: How sweet it is! J Clin Endocrinol Metab 1995;80:2279-2281.
15. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-16.
16. Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 1994;74:618-624.
17. Rocha RL, Hilsenbeck S, Jackson J, et al: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease free survival. Clin Cancer Res 1997;3: 103-109.
18. Rocha RL, Hilsenbeck SG, Jackson JG, et al: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996; 88:601-606.
19. Pratt S, Pollak M: Insulin-like growth factor binding protein 3 (IGFBP3) inhibits estrogenstimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994;198:292-297.
20. Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-649.
21. Huynh H, Yang X, Pollak M: A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 1996;7:1501-1506.
22. Gucev Z, Oh Y, Kelley K, et al: Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-1550.
23. Underwood LE, Murphy MG: Radioimmunoassay of the somatomedins/insulin-like growth factors; in Patrano C, Peskar BA (eds): Radioimmunoassay in Basic and Clinical Pharmacology. Berlin, Springer, 1987, pp 561-574.
24. Chatelain PG, Van Wyk JJ, Copeland CC, et al: Effects of in vitro action of serum proteases or exposure to acid on measurable immunoreactive somatomedin C in serum. J Clin Endocrinol Metab 1983;56:376-383.
25. Clemmons DR, Underwood LE, Chatelain PG, et al: Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin. J Clin Endocrinol Metab 1983;56:384-389.
26. Daughaday WH, Kapadia M, Moriz I: Serum somatomedin binding proteins: Physiologic significance and interference in radioligand assay. J Lab Clin Med 1987;109:355-363.
27. Daughaday WH, Mariz IK, Blethen SL: Inhibition of access of basic somatomedin to membrane receptors and immunobinding sites. A comparison of radioreceptor and radioimmunological somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 1980;51:781-788.
28. Baxter RC, Martin JL: Radioimmunoassay of growth factor hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 1986;78:1504-1512.
29. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, et al: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517.
30. Dickson RB, Lippman M: Growth factors in breast cancer. Endocr Rev 1995;16:559-589.
31. Clemmons DR, Underwood LE: Clinical Review 59: Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994;79:4-6.
32. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-320.
33. LeRoith D, Baserga R, Helman L, Roberts CT: Insulin-like growth factor and cancer. NIH Conference. Ann Intern Med 1995;22:54-59.
34. Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells. Breast Cancer Res Treat 1998;47:209-217.
35. Yee D: The insulin-like growth factors and breast cancer - revisited. Breast Cancer Res Treat 1998;47:197-199.
36. Pollak M, Costantino J, Polychronakos C, et al: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-1697.
37. Favoni RE, de Cupis A, Perrotta A, Sforzini S, Amoroso A, Pensa F, et al: Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early-and late-stage breast cancer: Mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol 1995; 121:674-682.
38. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al: Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993; 29A:492-497.
39. Friedl A, Jordan CV, Pollak M: Suppression of serum insulin-like growth factor I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368-1372.
40. Yamamoto H, Sohmiya M, Oka N, Kato Y: Effect of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinol (Copenh) 1991;124:497-500.
41. Pekonen F, Partanen S, Makinen T, et al: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 1988;48:1343-1347.
42. Peyrat JP, Bonneterre J, Beuscart R, et al: Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988;48: 6429-6433.
43. Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond) 1975;256:592-593.
44. Cole M, Jones CT, Todd IDH: A new antiestrogenic agent in late breast cancer: An early clinical appraisal of ICI 46,474. Br J Cancer 1971;25:270-275.
45. Colletti RB, Roberts JD, DeVlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882-1884.
46. Helle SI, Holly JM, Tally M, et al: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996;69:335-339.
47. Helle SI, Anker GB, Tally M, et al: Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996;57:167-171.
48. Kawamura I, Lacey E, Mizota T, et al: The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res 1994;14:427-431.
49. Bajetta E, Ferrai L, Celio L, et al: The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997;63:261-267.
50. Frost VJ, Helle SI, Lonning PE, et al: Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996;81:2216-2221.
51. Guvakova M, Surmacz E: Tamoxifen interferes with the insulin-like growth factor-I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-2610.
52. Dunn SE, Hardman RA, Kari FW, Barrett JC: Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced diverse anticancer drugs. Cancer Res 1997;57:2687-2693.
53. Helle SI, Lonning PE: Insulin-like growth factors in breast cancer. Acta Oncol 1996;35(suppl 5):19-22.